Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy-Reference-Cited by-同舟云学术

Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy

Published:2023-09 Issue:9 Volume:29 Page:567-571
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Davis James A.^ORCID,Sborov Douglas W.^ORCID,Wesson William^ORCID,Julian Kelley^ORCID,Abdallah Al-Ola^ORCID,McGuirk Joseph P.,Ahmed Nausheen^ORCID,Hashmi Hamza

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference22 articles.

1. Package insert: ABECMA (idecabtagene vicleucel), suspension for intravenous infusion,2021

2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021

4. Package insert: CARVYKTI (ciltacabtagene autoleucel), suspension for intravenous infusion,2022

5. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma;Chari;N Engl J Med,2019

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma;Transplantation and Cellular Therapy;2024-09

2. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma;Transplantation and Cellular Therapy;2024-09

3. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey;Frontiers in Medicine;2024-08-28

4. Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis;European Journal of Haematology;2024-08-27

5. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities;Intensive Care Medicine;2024-08-22